A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Helix Platform Granted the 1st and Only FDA Authorization for a Whole Exome Sequencing Platform

January 11, 2021

Helix has received de novo authorization from the U.S. Food & Drug Administration (FDA) for the Helix® Laboratory Platform, a whole exome sequencing platform with coverage of approximately 20,000 genes.

Helix advises this marks the first time such a broad, sequencing-based device has been authorized by the FDA. Additionally, Helix also received 510(k) clearance for the Helix® Genetic Health Risk App for late-onset Alzheimer’s Disease for over-the-counter use on the Helix Laboratory Platform.

Helix is excited to have collaborated with the FDA to pioneer a new regulatory pathway for a Whole Exome Sequencing Constituent Device (Regulation 21 CFR 866.6000) through the de novo authorization of the Helix Laboratory Platform. The analytical validation of the sequencing platform was conducted using a novel representative sampling-based approach in conjunction with rigorous quality metrics to establish the accuracy and reproducibility of the device.

This landmark market authorization of both a platform and its first test creates a defined regulatory path forward for Helix’s Sequence Once, Query OftenTM model. This enables Helix and its partners to develop and obtain market authorization for future tests using subsets of sequencing data generated from the Helix Laboratory Platform, including for cancer, cardiovascular disease, and carrier screening.

“Being the first company to receive market authorization for such a broad, sequencing-based platform is a major milestone for Helix and for the genomics industry,” said Dr. James Lu, M.D., Ph.D., co-founder, and President of Helix. “Our research has shown that many people are at risk for highly actionable genetic conditions that could be prevented with better access to genetic screening. This first-of-its-kind market authorization will greatly accelerate the adoption of genomic medicine that can personalize and improve the care that patients receive.”

“This is a very important milestone and highlights the growing role of genomics in clinical care,” said Francis deSouza, Illumina’s President and Chief Executive Officer. “We congratulate Helix on this authorization, which moves us another step closer to ensuring people have access to genomic insights that can transform their lives.”

“This tremendous collaboration with the FDA has allowed Helix to innovate a first-of-its-kind whole exome sequencing platform that will have a measurable impact on the ability to clear new genomic applications,” said Marc Stapley, Chief Executive Officer of Helix. “We are excited to have pioneered this new regulatory authorization pathway to help health systems, life sciences companies, and payers to accelerate the advancement of genomic discoveries from bench to bedside.”

SourceHelix
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.
The company announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad’s Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of tumor heterogeneity and disease progression at various stages.
Proteintech advises the new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space.
In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.
Lindus Health has taken learnings from this experience to build a bespoke "All-in-One Metabolic CRO" offering that combines the expertise of a seasoned full service CRO and internal site/PI expertise with a distinctive technology driven approach on its proprietary Citrusâ„¢ platform. This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.

By using this website you agree to accept Medical Device News Magazine Privacy Policy